N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide

• ChemBase编号: 1199
• 分子式: C13H15N3O4S
• 平均质量: 309.3409
• 单一同位素质量: 309.07832698
• SMILES: S(=O)(=O)(Nc1ncc(OCCOC)cn1)c1ccccc1
• Canonical SMILES: COCCOc1cnc(nc1)NS(=O)(=O)c1ccccc1
• InChI: InChI=1S/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)
• InChIKey: QFWPJPIVLCBXFJ-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: N-[5-(2-methoxyethoxy)pyrimidin-2-yl]benzenesulfonamide
• IUPAC传统名: glycodiazine
• 别名: Glymidine; Glidiazine; Glycodiazine

登记号

• CAS号: 339-44-6
• PubChem SID: 46507076; 160964661
• PubChem CID: 9565

理论计算性质

JChem

• Acid pKa: 6.9183197
• 质子受体: 6
• 质子供体: 1
• LogD (pH = 5.5): 0.9971591
• LogD (pH = 7.4): 0.5350139
• Log P: 1.0115399
• 摩尔折射率: 77.0072 cm^3
• 极化性: 30.371511 Å^3
• 极化表面积: 90.41 Å^2
• 可自由旋转的化学键: 6
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.27
• LOG S: -3.4
• 溶解度: 1.24e-01 g/l

详细说明

DrugBank - DB01382

• Drug Groups: approved
• Description: Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glycodiazine likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin. It is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
• Indication: Glycodiazine is used concomitantly with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus.
• Pharmacology: Glycodiazine is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
• Toxicity: Severe hypoglycemic reactions with coma, seizure, or other neurological impairment.
• Affected Organisms: Humans and other mammals
• Absorption: Rapidly and completely absorbed following oral administration.
• Half Life: 4 hours.
• Protein Binding: 90% bound to plasma proteins.